Document is current
Any future updates will be listed below
-
Authors
Kung, Heng-Chung
Zheng, Kevin W.
Zimmerman, Jacquelyn W.
Zheng, Lei https://orcid.org/0000-0003-4163-2541
- License Information
-
More Information
Article History
Accepted: 9 September 2025
First Online: 3 October 2025
Competing interests
: L.Z. has acted as a consultant and/or adviser of Akrevia/Xilio, Alphamab, Amberstone, Ambrx Biosion, Clinicaltrial Option, Duo Oncology, Fortress Biotech, Histosonics, Mingruizhiyao, NovaRock, QED and Tavotek, has received research funding from Abmeta, AstraZeneca, Bristol-Meyer Squibb and Merck and holds shares in Alphamab, Amberstone, Cellaration and Mingruizhiyao. J.W.Z. has received research funding from Roche Genentech. The other authors declare no competing interests.
